|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...5354555657585960616263...156157» |
- | sifalimumab (MDX-1103) / AstraZeneca
Enrollment change: A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus. (clinicaltrials.gov) - Oct 23, 2015
P2, N=42, Active, not recruiting, Sponsor: AstraZeneca
N=30 --> 42
- New trial: Workability in Patients With Seropositive Rheumatoid Arthritis (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=120, Not yet recruiting, Sponsor: Kaiser Franz Josef Hospital
- |||||||||| dimethyl fumarate / Generic mfg.
New P3 trial: StarTec: Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 (clinicaltrials.gov) - Oct 23, 2015
P3, N=221, Active, not recruiting, Sponsor: Biogen
- || Trial primary completion date: Threshold Suspend in Pediatrics at Home (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=300, Enrolling by invitation, Sponsor: Medtronic Diabetes
N=30 --> 42 Trial primary completion date: Dec 2016 --> Mar 2017
- Trial primary completion date: Post-Radioiodine Graves' Management: The PRAGMA-Study (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=750, Recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Mar 2014 --> Feb 2015
- Biomarker, Trial primary completion date: A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action (clinicaltrials.gov) - Oct 22, 2015
P4, N=200, Recruiting, Sponsor: Medical University of Vienna
Trial primary completion date: Mar 2014 --> Feb 2015 Trial primary completion date: Jun 2015 --> Jun 2017
- Trial primary completion date: EPICOM: Study of Offspring of Women With Type 1 Diabetes (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=584, Active, not recruiting, Sponsor: Odense University Hospital
Trial primary completion date: Jun 2015 --> Jun 2017 Trial primary completion date: Aug 2015 --> Apr 2015
- Trial primary completion date, Immunomodulating: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=18, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Aug 2015 --> Apr 2015 Trial primary completion date: Mar 2015 --> Mar 2017
- prednisone / Generic mfg.
Trial termination: Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2015
P4, N=40, Terminated, Sponsor: Claudio Gobbi
Trial primary completion date: Mar 2015 --> Mar 2017 Recruiting --> Terminated; Difficulties to recruit patients
- || Betaseron (IFN-?-1b) / Bayer
Enrollment change: Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=68, Active, not recruiting, Sponsor: Bayer
Recruiting --> Terminated; Difficulties to recruit patients N=50 --> 68
- Campath (alemtuzumab) / Sanofi
Enrollment change: A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 22, 2015
P1, N=0, Withdrawn, Sponsor: University of Wisconsin, Madison
N=50 --> 68 N=50 --> 0
- New trial: Evolution of Effectiveness of Diabetes Medical Care in Russia (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=600, Recruiting, Sponsor: Endocrinology Research Centre, Moscow
- New trial: Impacts of Different Training Modes (Intense Versus Ordinary) on the Immune System and Memory Functions in pwMS (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=80, Recruiting, Sponsor: Klinik Valens
- ||||| New P4 trial: Effect of Fingolimod on Neurodegeneration (clinicaltrials.gov) - Oct 22, 2015
P4, N=120, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Ilaris (canakinumab) / Novartis
Enrollment change, Trial withdrawal, Trial primary completion date: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (clinicaltrials.gov) - Oct 22, 2015
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=50 --> 0 N=220 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2015 --> Jan 2015
- |||||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P3 trial, Combination therapy: The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM (clinicaltrials.gov) - Oct 22, 2015
P3, N=170, Not yet recruiting, Sponsor: AstraZeneca
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P1 trial, Combination therapy: The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM (clinicaltrials.gov) - Oct 22, 2015
P1, N=30, Not yet recruiting, Sponsor: AstraZeneca
- New P1 trial: Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes (clinicaltrials.gov) - Oct 22, 2015
P1, N=20, Recruiting, Sponsor: Leilei Zhu
- ||||| BI 695500 (rituximab biosimilar) / Boehringer Ingelheim
Enrollment closed, Trial primary completion date: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 22, 2015
P3, N=306, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=220 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2015 --> Jan 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Oct 2015
- Trial completion: Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA) (clinicaltrials.gov) - Oct 21, 2015
P1, N=9, Completed, Sponsor: Kang Stem Biotech Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Oct 2015 Recruiting --> Completed
- Trial completion: Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin (clinicaltrials.gov) - Oct 21, 2015
P0, N=36, Completed, Sponsor: William Sansum Diabetes Center
Recruiting --> Completed Active, not recruiting --> Completed
- ||| remtolumab (ABT-122) / AbbVie
Enrollment closed, P2 data, Enrollment change: Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study (clinicaltrials.gov) - Oct 21, 2015
P2, N=163, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | N=115 --> 163
- Enrollment closed: An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis (clinicaltrials.gov) - Oct 21, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Haley Duncanson
Enrolling by invitation --> Active, not recruiting | N=115 --> 163 Recruiting --> Active, not recruiting
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri (clinicaltrials.gov) - Oct 21, 2015
P=N/A, N=400, Completed, Sponsor: Biogen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, Trial initiation date, Trial primary completion date, HEOR: Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study (clinicaltrials.gov) - Oct 21, 2015
P=N/A, N=100, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Nov 2010 --> Dec 2012 | Trial primary completion date: Sep 2015 --> Sep 2014
- Enrollment closed: The ANCA Vasculitis Questionnaire (AAV-PRO (clinicaltrials.gov) - Oct 20, 2015
P=N/A, N=500, Active, not recruiting, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed | Initiation date: Nov 2010 --> Dec 2012 | Trial primary completion date: Sep 2015 --> Sep 2014 Recruiting --> Active, not recruiting
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed, Monotherapy: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) (clinicaltrials.gov) - Oct 20, 2015
P3, N=90, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Oct 20, 2015
P=N/A, N=43, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jul 2015
- Trial completion: Balance and Falls in Multiple Sclerosis (clinicaltrials.gov) - Oct 17, 2015
P=N/A, N=52, Completed, Sponsor: Örebro County Council
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jul 2015 Active, not recruiting --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen
Trial completion, Trial primary completion date: IIT6: Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design (clinicaltrials.gov) - Oct 17, 2015
P=N/A, N=30, Completed, Sponsor: Rocky Mountain MS Research Group, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Sep 2014
- Trial completion, Enrollment change, Trial primary completion date: Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 16, 2015
P=N/A, N=85, Completed, Sponsor: Odense University Hospital
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Sep 2014 Recruiting --> Completed | N=130 --> 85 | Trial primary completion date: Apr 2015 --> Sep 2015
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Combination therapy: ACUTE-JIA: Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Oct 16, 2015
P3, N=60, Completed, Sponsor: Helsinki University Central Hospital
Recruiting --> Completed | N=130 --> 85 | Trial primary completion date: Apr 2015 --> Sep 2015 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Genetic Study of Lupus Patients and Their Families (clinicaltrials.gov) - Oct 16, 2015
P=N/A, N=2356, Completed, Sponsor: Oklahoma Medical Research Foundation
Active, not recruiting --> Completed Recruiting --> Completed | N=5000 --> 2356 | Trial primary completion date: Jun 2011 --> Mar 2013
- Trial completion, Enrollment change: LFRR: Lupus Genetics Studies (clinicaltrials.gov) - Oct 16, 2015
P=N/A, N=3460, Completed, Sponsor: Oklahoma Medical Research Foundation
Recruiting --> Completed | N=5000 --> 2356 | Trial primary completion date: Jun 2011 --> Mar 2013 Recruiting --> Completed | N=18000 --> 3460
- Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Enrollment closed: The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes (clinicaltrials.gov) - Oct 15, 2015
P1, N=15, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed | N=18000 --> 3460 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date, Patient reported outcomes: 25-hydroxyvitamin D and Fatigue: The VITALITY Study (clinicaltrials.gov) - Oct 15, 2015
P=N/A, N=614, Completed, Sponsor: Ostfold Hospital Trust
Recruiting --> Active, not recruiting Not yet recruiting --> Completed | N=1100 --> 614 | Trial primary completion date: Jun 2014 --> Nov 2014
- |||| Trial completion, Trial primary completion date: Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (clinicaltrials.gov) - Oct 15, 2015
P4, N=150, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Completed | N=1100 --> 614 | Trial primary completion date: Jun 2014 --> Nov 2014 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015
- ||||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
Enrollment closed: VOLTAIRE-RA: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Oct 15, 2015
P3, N=650, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015 Recruiting --> Active, not recruiting
- | Trial completion: Safety Study of Immune System Modulator for Autoimmune Diseases (clinicaltrials.gov) - Oct 14, 2015
P1, N=18, Completed, Sponsor: Artax Biopharma Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Trial completion: Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents (clinicaltrials.gov) - Oct 14, 2015
P=N/A, N=166, Completed, Sponsor: AbbVie
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Nucala (mepolizumab) / GSK
Enrollment closed: A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (clinicaltrials.gov) - Oct 13, 2015
P3, N=130, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| methotrexate / Generic mfg., paracetamol / Generic mfg.
Trial completion, Trial primary completion date: The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 10, 2015
P2, N=240, Completed, Sponsor: Maoxiang Group Jilin Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015
- Enrollment closed: DIMMISI: Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS (clinicaltrials.gov) - Oct 9, 2015
P=N/A, N=144, Active, not recruiting, Sponsor: Niguarda Hospital
Recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date, Adherence: Adherence-SLE: International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 8, 2015
P=N/A, N=307, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Dec 2015
- | azathioprine / Generic mfg.
Trial completion: CHUSPAN2: Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) (clinicaltrials.gov) - Oct 8, 2015
P3, N=114, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Dec 2015 Active, not recruiting --> Completed
- Trial completion, Phase classification: TeensConnect: Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=124, Completed, Sponsor: Yale University
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P3 --> PN/A
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
New trial: Tocihelper: Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=60, Recruiting, Sponsor: Association Aquitaine de Recherche Clinique en Rhumatologie
- |||| BI 695500 (rituximab biosimilar) / Boehringer Ingelheim
Trial primary completion date: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis (clinicaltrials.gov) - Oct 7, 2015
P3, N=250, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A Trial primary completion date: Dec 2016 --> Jan 2016
- Trial primary completion date: Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial) (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=88, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2016 --> Jan 2016 Trial primary completion date: Sep 2015 --> Dec 2015
- Trial initiation date: Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis (clinicaltrials.gov) - Oct 7, 2015
P2, N=48, Not yet recruiting, Sponsor: Louisiana State University Health Sciences Center in New Orleans
Trial primary completion date: Sep 2015 --> Dec 2015 Initiation date: Sep 2015 --> Dec 2015